• Oury Medical

  Participated · Equity · Apr 2026

  Oury Medical specializes in manufacturing orthopedic and spinal surgical instruments and implants and has grown through a series of targeted acquisitions since 2022. The group reports more than €25 million in revenue and employs nearly 200 people across five production sites following its latest acquisition of Céfiméca. Oury Medical’s recent fundraising of over €30 million was used to acquire Céfiméca and support planned industrial investments to optimize production. The company expanded rapidly from €5 million in revenue in 2022 to over €25 million by 2025, driven by acquisitions and investments in production and operational efficiency. Backed by Tag Partners (majority investor since 2022) and new investor Isalt (via the FST), Oury Medical intends to pursue further targeted purchases to consolidate its position on major global markets and aim to become a leading European player in orthopedics and spine surgery.

• Spareka

  Participated · Series B · Mar 2023

  Spareka operates an online marketplace that helps consumers find and buy replacement parts and connects them with trained specialists who guide repairs via video call. Founded in 2012 and based in France, the company also handles shipping of parts to customers. Since 2012 more than 1 million customers have repaired devices via Spareka, which the company says equates to 41,000 tonnes of CO2 avoided. Financially, Spareka reported €10 million of turnover in 2022, with its marketplace figures growing 166% and videoconferencing revenues up 128%. The fresh capital will support a pan-European expansion with launches planned in Germany, Spain, and Portugal. The service aims to simplify diagnosis, parts sourcing, and guided fixes to encourage repair over replacement.

• Hackuity

  Participated · Equity · Mar 2022

  Hackuity builds a vulnerability-management platform that normalises and aggregates customers' third-party exposure data into a single pane of glass and analytical engine. The product is designed to break technological silos so security teams can collect, prioritise, and remediate security weaknesses before they are exploited. The company emerged from stealth with external funding and serves enterprise security teams and leaders seeking an objective way to quantify and improve security posture. Hackuity was founded to revitalise vulnerability management as a foundational security practice. Financially, the startup announced a €12 million funding round to support growth. Going forward it plans to accelerate its core strategy across 2022 and 2023, pursue international expansion in major markets, and expand its engineering team with a focus on diversity and inclusion.

• Saqara

  Participated · Series A · Sep 2021

  Saqara is a bid management software platform that centralizes the procurement and tendering process for building and construction projects. Its platform is used by project managers, contracting authorities, general contractors and construction companies to manage tenders from initiation through contractual signing. In 2020 the company launched Chantier Privé par Saqara, a complementary digital marketplace that connects construction companies and project developers by geography, project size and type. The company has expanded into Belgium, Luxembourg and Switzerland and established a Tunisian strategic hub to accelerate its MENA footprint. Saqara reports having launched 4,500 projects on its platform since 2018, totaling over €18 billion of construction and infrastructure works; it employs 120 people, serves more than 500 clients, has 50,000 users and over 25,000 referenced contractors. It intends to use recent funding to support international growth in key markets such as the UK, Germany, the Netherlands and North Africa.

• Ynsect

  Participated · Series C · Oct 2020

  Ÿnsect produces natural insect protein and is shifting its commercial focus from primarily animal feed to pet foods and food ingredients. The company says the new capital will support that pivot toward higher-margin markets. Ÿnsect cited soaring costs—energy, raw materials and the cost of capital and debt—as a driver for refocusing its operations. As part of the refocus it will close a Dutch production plant acquired via Protifarm about two years ago. The shutdown triggers 35 immediate job cuts and a further 38 positions slated to go, from a workforce of 360 (a 20.27% reduction). Management says the move responds to market dynamics where animal feed is less remunerative than pet-food and food-ingredient markets. The company declined to disclose investors for the newest raise and said a second tranche is in discussion. Ÿnsect farms mealworms that produce protein ingredients for animal feed and fertilisers and is constructing a large insect farm in Amiens, north France. The company says it will complete construction in 2022 and produce 100,000 tons of insect products annually. Ÿnsect plans to use the new funding to finance expansion into the US. Management frames the technology as a more sustainable way to produce food inputs amid climate change and growing populations. The company reported that Covid-19 had little impact on its workflow this year. Its total funding to date now stands at $425 million. Ÿnsect produces insect-derived protein at scale using mealworms and automated, sensor-driven cultivation technologies. The company applies automation and sensing technologies from industries like automotive and data centers, holds 25 patents, and uses an AI-enabled, fully automated production process. Its products are sold into pet food, plant food and aquaculture animal feed markets, with particular emphasis on fish and shellfish farming. Ÿnsect is expanding globally and plans to build what it calls the world’s biggest insect farm in Amiens Métropole in northern France, while beginning expansion into the North American market. The company is on track to book more than $70 million in revenue this year. Management has signaled a goal of reaching unicorn status as it scales production and market reach. Ynsect is an innovation company that farms and transforms insects into high-quality natural diets for livestock and pet nutrition, and potentially human nutrition in the longer term. Its main product is TMP — Tenebrio molitor protein — a de-fatted protein meal made from farmed mealworm larvae. The company has designed proprietary technology to farm mealworm larvae, using automation and machine-learning software connected to sensors to ensure insect welfare, promote growth, and safeguard operators' health. Ynsect intends to increase capacity at Ynsite, its pilot centre in Jura, France, and to begin preparatory engineering for a large insect unit targeted to produce at least 20,000 metric tons of insect protein per year. The company closed a $15.2M Series B, bringing cumulative private and public funding to $37M over the prior three years. Founded in 2011 and based in Evry, France, Ynsect focuses on scaling mass-breeding and processing of mealworms for the animal feed market. Ynsect is a French insect biotechnology company founded in 2011 that has developed Entoraffinerie© for the nutritional and green chemistry markets. The company has run major R&D programs with academic and research institutions across France and Europe, including CEA, INRA, CNRS, IFREMER, AgroParisTech, IRSTEA and Wageningen University. Ynsect raised €5.5m in funding from New Protein Capital alongside existing investors Emertec Gestion and Demeter Partners. The company intends to use the funds to advance its solution, accelerate R&D in a new 1,700 m² facility at Genopole in Évry, and begin industrializing its processes. Ynsect also plans to strengthen its international position, particularly in Asia, and continue developing partnerships with manufacturing companies abroad. It is supported by Bpifrance and the Île-de-France Region.

No current team members are available.